News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Sanofi-Aventis (France) Prepares to Raise Genzyme Corporation Bid as GlaxoSmithKline Denies Plans to Step in as Rival Bidder
September 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS, Sept 7 (Reuters) - GlaxoSmithKline (GSK.L) will not step in as a rival bidder for U.S. biotech Genzyme (GENZ.O) and take on Sanofi-Aventis (SASY.PA), the British drugmaker's head of research and development told a French newspaper.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
GlaxoSmithKline
Sanofi
MORE ON THIS TOPIC
Mergers & acquisitions
Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos
March 24, 2026
·
3 min read
·
Tristan Manalac
Immunology and inflammation
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+
March 23, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
March 20, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One
March 19, 2026
·
2 min read
·
Tristan Manalac